



AMENDMENT NO. _____ Calendar No. _____

Purpose: In the nature of a substitute.

IN THE SENATE OF THE UNITED STATES—118th Cong., 1st Sess.

S. 1280

To require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.

Referred to the Committee on _____ and ordered to be printed

Ordered to lie on the table and to be printed

AMENDMENT IN THE NATURE OF A SUBSTITUTE intended to be proposed by Mr. CRUZ

Viz:

1 Strike all after the enacting clause and insert the following:
2

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023” or the
5
6 “TRANQ Research Act of 2023”.

7 **SEC. 2. XYLAZINE DETECTION AND ANALYSIS.**

8 (a) DEFINITIONS.—In this section:

9 (1) DIRECTOR.—The term “Director” means
10 the Director of the National Institute of Standards
11 and Technology.

1 (2) FEDERAL LABORATORY.—The term “Fed-
2 eral laboratory” has the meaning given such term in
3 section 4 of the Stevenson-Wydler Technology Inno-
4 vation Act of 1980 (15 U.S.C. 3703).

5 (3) INSTITUTE.—The term “Institute” means
6 the National Institute of Standards and Technology.

7 (4) INSTITUTION OF HIGHER EDUCATION.—The
8 term “institution of higher education” has the
9 meaning given such term in section 101 of the High-
10 er Education Act of 1965 (19 U.S.C. 1001).

11 (5) NONPROFIT ORGANIZATION.—The term
12 “nonprofit organization” means an organization de-
13 scribed in section 501(c)(3) of the Internal Revenue
14 Code of 1986 and exempt from tax under section
15 501(a) of such code.

16 (6) XYLAZINE.—The term “xylazine” means
17 the nonopioid tranquilizer methyl benzene compound
18 frequently used in veterinary medicine as an emetic
19 and sedative with analgesic and muscle relaxant
20 properties.

21 (b) IN GENERAL.—The Director shall—

22 (1) support intramural basic measurement
23 science and research of the Institute to advance—

24 (A) analytical methods to identify, under-
25 stand, differentiate, and categorize substances

1 containing xylazine, novel synthetic opioids, or
2 other new psychoactive substances;

3 (B) measurement technologies to shorten
4 analysis timelines and enhance narcotic and
5 opioid detection and analysis capabilities;

6 (C) new data tools, techniques, and proc-
7 esses to identify and publicly disclose relevant
8 information concerning substances containing
9 xylazine, novel synthetic opioids, or other new
10 psychoactive substances; and

11 (D) such other areas as the Director deter-
12 mines to be critical to the development and de-
13 ployment of technologies to measure and ana-
14 lyze the presence of xylazine, novel synthetic
15 opioids, and other new psychoactive substances;

16 (2) support activities to inform and expand the
17 development of near-real time spectrometry capabili-
18 ties regarding xylazine, novel synthetic opioids, and
19 other new psychoactive substances;

20 (3) convene the private sector, institutions of
21 higher education, nonprofit organizations, Federal
22 laboratories, intergovernmental organizations, and
23 other Federal agencies, including the Center for Dis-
24 ease Control and Prevention, and the National Insti-
25 tute on Drug Abuse, engaged in the analysis of new

1 psychoactive substances to develop coordinated strat-
2 egies and voluntary best practices for the safe han-
3 dling, transport, data-sharing, and analysis of sub-
4 stances containing xylazine, novel synthetic opioids,
5 or other new psychoactive substances;

6 (4) establish or expand collaborative partner-
7 ships or consortia with other government agencies
8 and persons engaged in related research and devel-
9 opment, such as institutions of higher education,
10 Federal laboratories, public health agencies, inter-
11 governmental organizations, and the private sector,
12 to enhance narcotic and opioid detection and anal-
13 ysis capabilities regarding xylazine, novel synthetic
14 opioids, and other new psychoactive substances; and

15 (5) provide opportunities for graduate and post-
16 graduate research on the detection and identification
17 of xylazine, novel synthetic opioids, and other new
18 psychoactive substances.

19 (c) **CONTROLS.**—In carrying out activities under this
20 section, the Director shall ensure proper security controls
21 are implemented to protect sensitive information, as the
22 Director considers appropriate and consistent with appli-
23 cable provisions of law.

24 (d) **REPORT.**—Not later than 1 year after the date
25 of the enactment of this Act, the Director shall submit

1 to the Committee on Commerce, Science, and Transpor-
2 tation of the Senate and the Committee on Science, Space,
3 and Technology of the House of Representatives a report
4 on the implementation of this section. Such report may
5 include recommendations for legislative action to improve
6 the ability of the Director to carry out this section.